Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG161 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
NCT07505615Phase 2Completed
- Start
- Oct 2021
- Primary completion
- Apr 2023
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of VG161 in non-muscle-invasive bladder cancer (NMIBC). Primary endpoints: Relapse-Free Survival at 12 months and Incidence of treatment-related adverse events at 12 months. Started Oct 2021; status: completed.
02
Drugs
VG161
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07505615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07505615.